From ImmusanT Press Release
20 October 2018
Cambridge, MA
“CAMBRIDGE, Mass. – October 30, 2018 – ImmusanT, Inc., a clinical stage company leveraging
its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based
immunomodulatory vaccine therapies to patients with autoimmune diseases, initiated
enrollment in Australia and New Zealand for its Phase 2 RESET CeD study assessing the safety,
tolerability and efficacy of its lead therapeutic candidate, Nexvax2®, in patients with celiac
disease who carry the immune recognition genes for HLA-DQ2.5. The latter accounts for
approximately 90% of the celiac patient population, and Nexvax2 is designed to protect these
patients from the effects of gluten exposure … read more here and here
Other articles related to the Nexvax2 Phase 2 Trials
